Nanowear | January 5, 2018
NEW YORK, Jan. 5, 2018 /PRNewswire/ — Nanowear, the leader in cloth-based diagnostic monitoring nanosensor technology, today announced that it has entered into an exclusive, worldwide supply-chain partnership agreement with The Secant Group for scaled manufacturing and production of its medical-grade cloth-based nanosensor technology. Under the terms of the agreement, Nanowear and The Secant Group will have the collective obligation for marketing the technology and associated products.
Upon receiving FDA 510(k) clearance as the first, and only, cloth-based remote cardiac monitoring technology platform, Nanowear turned its attention to commercialization opportunities and engaging a manufacturing partner that possessed the unique and very specific materials and textile capabilities required for scaled production of its proprietary nanosensor technology. “Since our FDA approval one year ago, we have worked exhaustively to find the right materials technology partner and we could not be happier in this announcement with The Secant Group and their sister company SanaVita Medical. Secant is a perfect fit in terms of design, development, and manufacturing of medical device components and specifically, biomedical textiles, in an ISO 13485 certified facility. SanaVita Medical brings contract manufacturing and medical device processing services including finishing and assembly, packaging and labeling, and regulatory registration and compliance as an FDA registered facility,” says Nanowear Co-founder & CEO, Venk Varadan.
Additionally, Nanowear has continued pre-commercialization development of its undergarment and alert analytics product in Congestive Heart Failure (CHF) management, and The Secant Group’s manufacturing capabilities will be integral for scaling product inventory as the company plans to commence a large clinical trial in 2018.